May 2018

New Product - Dupixent

Dupixent (dupilumab (rch)) is a fully human recombinant monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupixent inhibits IL-4 signaling via the type I receptor (IL-4Rα/γc), and both IL-4 and IL-13 signaling through the type II receptor (IL-4Rα/IL-13Rα). IL-4 and IL-13 are key type 2 (including Th2) cytokines involved in atopic disease. Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in adults who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use. Dupixent prefilled syringe (300 mg/2 mL) is available in packs of 2.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au